Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6436 to 6450 of 8314 results

  1. Actinic keratosis: ingenol mebutate gel (ESNM14)

    This evidence summary has been withdrawn as the licence of ingenol mebutate gel has been suspended.

    Evidence summary
    Published
    19 March 2013

  2. Schizophrenia: lurasidone (ESNM15)

    This evidence summary has been replaced by ESNM48

    Evidence summary
    Published
    9 April 2013

  3. Irritable bowel syndrome with constipation in adults: linaclotide (ESNM16)

    This evidence summary has been updated and replaced by NICE guideline CG61.

    Evidence summary
    Published
    9 April 2013

  4. Partial-onset seizures in epilepsy: zonisamide as monotherapy (ESNM17)

    This evidence summary has been updated and replaced by NICE guideline NG217.

    Evidence summary
    Published
    16 April 2013

  5. Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)

    This evidence summary has been updated and replaced by NICE guideline CG97.

    Evidence summary
    Published
    23 May 2013

  6. Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate (ESNM19)

    This evidence summary has been updated and replaced by NICE guideline NG87.

    Evidence summary
    Published
    7 May 2013

  7. Idiopathic overactive bladder syndrome: botulinum toxin A (ESNM2)

    This evidence summary has been replaced by NICE guideline CG171.

    Evidence summary
    Published
    1 September 2012

  8. Type 2 diabetes: alogliptin (ESNM20)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Evidence summary
    Published
    21 May 2013

  9. Chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol (ESNM21)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    18 June 2013

  10. Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment (ESNM22)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Evidence summary
    Published
    25 June 2013

  11. Gouty arthritis: canakinumab (ESNM23)

    This advice has been updated and replaced by NICE guideline NG219.

    Evidence summary
    Published
    23 July 2013

  12. Type 1 diabetes: insulin degludec (ESNM24)

    This evidence summary has been updated and replaced by NICE guideline NG17.

    Evidence summary
    Published
    10 September 2013

  13. Type 2 diabetes: lixisenatide (ESNM26)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Evidence summary
    Published
    24 September 2013

  14. Secondary prevention in acute coronary syndrome: rivaroxaban (ESNM27)

    This evidence summary has been replaced by NICE technology appraisal guidance 335

    Evidence summary
    Published
    29 October 2013

  15. Transobturator foramen procedures for stress urinary incontinence (IPG107)

    The National Institute for Health and Clinical Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on transobturator foramen procedures for stress incontinence in January 2005. This guidance has been withdrawn as the use of this procedure is now covered in NICE guideline CG40. NICE has no plans to carry out further assessment of this procedure under the Interventional Procedures Programme.

    Interventional procedures guidance
    Published
    23 January 2005